Daniel P. Petrylak, MD, presented “FDA Approves Pembrolizumab for New Indication of NMIBC” for the Grand Rounds in Urology audience in January 2020.
How to cite: Petrylak, Daniel P. “FDA Approves Pembrolizumab for New Indication of NMIBC” January, 2020. Accessed May 2021. https://grandroundsinurology.com/late-breaking-fda-approves-pembrolizumab-for-new-indication-of-nmibc/
FDA Approves Pembrolizumab for New Indication of NMIBC – Summary:
Daniel P. Petrylak, MD, discusses the recent FDA approval of the checkpoint inhibitor pembrolizumab for treating cystectomy-ineligible (or those who have refused cystectomy) non-muscle invasive bladder cancer patients who have also failed BCG. He details the prior lack of available treatment for this disease, explains the function of the drug as a checkpoint inhibitor, and describes the study that led to the drug’s approval.